Registration - In-house Corporation

Eli Lilly Canada Inc. / Kenneth L Custer, President and General Manager

Registration Information

In-house Corporation name: Eli Lilly Canada Inc.
Responsible Officer Name: Kenneth L Custer, President and General Manager
Responsible Officer Change History
Initial registration start date: 2005-12-19
Registration status: Active
Registration Number: 954779-6034

Associated Communications

Total Number of Communication Reports: 145

Monthly communication reports in the last 6 months: 0

Version 29 of 35 (2022-05-05 to 2023-02-01)

Registration versions:

Version 29 of 35 (2022-05-05 to 2023-02-01)

Lobbying Information

Subject Matters

Economic Development
Health
Industry
Intellectual Property
International Trade
Research and Development
Science and Technology
Taxation and Finance

Subject Matter Details

Legislative Proposal, Bill or Resolution

Food and Drug Act - An Act respecting food, drugs, cosmetics and therapeutic devices. Discussions relating to progressive licensing and the modernization of the Food and Drug Act.
Patent Act - An Act respecting patents of invention with regard to Intellectual Property Protection for pharmaceutical products - federal court decisions that have changed the disclosure requirements regarding the utility of an invention.

Policies or Program

Free trade treaty agreement as it relates to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to Columbia, India, and the European Union
Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
The government's Science and Technology Strategy potential policies and programs pertaining to the biopharmaceutical industry

Regulation

Intellectual Property - Changes to Patented Medicine (Notice of Compliance) (PMNOC) regulations - important regulations that can affect Eli Lilly Canada's business
Patented Medicine Notice of Compliance (PMNOC) Regulations - enforcement of Intellectual Property with respect to the Canadian pharmaceutical industry.
Patented Medicines Pricing Review Board (PMPRB) – regulations that can impact the Canadian pharmaceutical industry.

Communication Techniques

Written communication
Oral communication

Government Institutions

Agriculture and Agri-Food Canada (AAFC)
Federal Economic Development Agency for Southern Ontario (FedDev)
Finance Canada (FIN)
Global Affairs Canada (GAC)
Great Lakes Pilotage Authority
Health Canada (HC)
House of Commons
Innovation, Science and Economic Development Canada (ISED)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Public Health Agency of Canada (PHAC)
Senate of Canada
Treasury Board Of Canada Secretariat (TBS)

In-house Corporation Details

Description of activities

Pharmaceutical manufacturer, research and development, commercial operations.

Responsible officer name and position during the period of this registration

Rhonda Pacheco, President and General Manager

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
P. O. Box 73, Exchange Tower
130 King Street West, Suite 900
Toronto, ON M5X 1B1
Canada

Telephone number: 416-699-7222
Fax number: 416-694-0487

Parent Company Information

Eli Lilly & Company
- Lilly Corporate Center
  Indianapolis, IN 46225
  United States of America

Subsidiary Beneficiary Information

BIOTECANADA
- (Partner)
  1 Nicholas Street, Suite 600
  OTTAWA, ON K1N 7B7
  Canada
Innovative Medicines Canada / Medicaments Novateurs Canada
- (Partner)
  55 Metcalfe Street, Suite 1220
  Ottawa, ON K1P 6L5
  Canada

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Jill Daley, General Counsel & Corporate Secretary | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Christopher Praught, Sr. Manager, Policy & Government Relations, Corporate Affairs | Designated public offices held

Eli Lilly Canada Inc.

The following names have been used on or after July 2, 2008

The following names have been used on or after July 2, 2008
Name	From	To
Eli Lilly Canada Inc.	2009-07-06	current

The following names have been used before July 2, 2008

Eli Lilly Canada Inc.

Eli Lilly Canada Inc.

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Kenneth L Custer	2023-05-01	Current
Rhonda Pacheco	2020-02-01	2023-05-01
Lisa Matar	2013-06-04	2020-02-01
Michael Mason	2012-10-02	2013-06-04
David Ricks	2005-12-19	2012-10-02

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Senior Policy and Regional Affairs Advisor Natural Resources Canada, Minister's Office	August 2012 to November 2015	November 30, 2015
Director of Policy Public Works and Government Services Canada, Minister's Office	December 2009 to August 2012	August 3, 2012
Policy Advisor Employment and Social Development Canada - Labour Program, Minister's Office	May 2009 to December 2009	December 1, 2009
Senior Special Assistant Western Economic Diversification, Minister's Office	August 2007 to April 2009	April 30, 2009
Parliamentary Assistant House of Commons of Canada, MP Office	September 2006 to August 2007	Not a designated office

Date Modified:: 2025-03-12

Search and menus

Language selection

Registration - In-house Corporation

Eli Lilly Canada Inc. / Kenneth L Custer, President and General Manager

Registration Information

Associated Communications

Version 29 of 35 (2022-05-05 to 2023-02-01)

Version 29 of 35 (2022-05-05 to 2023-02-01)

Subject Matters

Subject Matter Details

Legislative Proposal, Bill or Resolution

Policies or Program

Regulation

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties